Venaxis, Inc. (NASDAQ:APPY) issued a press release announcing the closing of its previously announced underwritten public offering of shares of its common stock. Venaxis Inc (NASDAQ:APPY) shares after opening at $2.31 moved to $2.35 on last trade day and at the end of the day closed at $2.23. Company price to sales ratio in past twelve months was calculated as 1216.62 and price to cash ratio as 3.94. Venaxis Inc (NASDAQ:APPY) showed a positive/negative weekly performance of 3.24%.
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced new appointments to its board of directors. Current board member, Gino Santini, has been elected, by unanimous vote, to chairman of the board of directors, effective immediately, taking over for Mike Narachi. Mr. Narachi informed the board that, after eight years of service, he has decided not to stand for re-election at this year’s upcoming annual shareholder meeting in May 2014. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares advanced 0.73% in last trading session and ended the day on $17.88. AMAG return on equity ratio is recorded as -5.60% and its return on assets is -3.70%. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) yearly performance is -15.54%.
Palatin Technologies, Inc (NYSE:PTN) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Tuesday, ARN reports. Palatin Technologies, Inc. (NYSEMKT:PTN) shares moved up 0.90% in last trading session and was closed at $1.12 while trading in range of $1.04 – $1.13 – Palatin Technologies, Inc. (NYSEMKT:PTN) year to date (YTD) performance is 54.11%.
IDEXX Laboratories, Inc. (NASDAQ:IDXX), has scheduled the release of its 2014 first quarter financial results for Friday, April 25, at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. IDEXX Laboratories, Inc. (NASDAQ:IDXX) weekly performance is -1.42%. On last trading day company shares ended up $117.94. IDEXX Laboratories, Inc. (NASDAQ:IDXX) distance from 50-day simple moving average (SMA50) is -4.23%. Analysts mean target price for the company is $121.00.